From Detection to Prediction: Analytical Approaches for Nitrosamine Risk

Nitrosamines have been known carcinogens for decades, but their emergence in pharmaceutical products in 2018 transformed them into a central regulatory and analytical priority.1 What began as a targeted investigation into a handful of small nitrosamines has since expanded into a complex, mechanism-driven discipline requiring predictive assessment, structural evaluation, and highly sensitive analytical methods.

Today, nitrosamine control is no longer about detecting a short list of known impurities. It is about understanding why nitrosamines form, where they may form across the product life cycle, and how to anticipate and prevent their formation.

The Hidden Complexity of Nitrosamine Formation

Nitrosamine formation depends on 2 components: a nitrosating agent (typically nitrites) and an amine. Nitrites can come from many sources, including nitrous acid, nitric oxides, and nitrates. When nitrites become acidified, they form nitrous acid, which can then react with an amine to generate a nitrosamine. They are metabolically activated in the liver, thereby allowing them to cause DNA alkylation. This activation produces reactive intermediates that can induce base-pair mutations, particularly at the O6-guanine position, during DNA replication.1,2

Two features make nitrosamines uniquely challenging. First, when a nitrosamine is formed, it is stable and will not readily degrade into something else. Second, unlike elemental impurities or leachables, nitrosamine risk is not mitigated by oral administration. All routes of administration (oral, inhaled, injectable, topical products, etc) carry similar toxicological concerns. This toxicological profile underpins the stringent acceptable intake (AI) limits, often in the low nanograms-per-day range, and the need for predictive, rather than reactive, control strategies.

Nitrites arise from numerous sources, including plant- or animal-derived excipients and processing residuals, and are commonly present in water at low levels. Even a low level of nitrites may slightly exceed the nitrosamine concern threshold. Typical nitrite levels from common excipients can average approximately 1 ppm—orders of magnitude higher than the nanogram-level thresholds relevant for nitrosamines.3 These excipients are commonly used in pharmaceutical products to optimize the safety and delivery of the active ingredient.

Secondary, tertiary, and quaternary amines are widespread in pharmaceuticals because they drive therapeutic activity. This ubiquity means many APIs inherently contain a “nitrosatable” site. Even if no nitrosamine is present in the API or excipient, the presence of an amine alone constitutes half of the formation pathway.

Conditions that drive formation. Nitrosation typically requires acidic conditions, which may arise during the following:

• granulation
• coating
• pH‑adjusted processing steps
• stability (eg, moisture‑driven hydrolysis)

CLICK HERE TO READ THE FULL ARTICLE